Levino da Costa Meneses 1, Michele de Sá Ribeiro 1, Maria Carolina Anholeti 2, 4, Maria Raquel Figueiredo 3, Maria Auxiliadora Coelho Kaplan 4, Marcelo Guerra Santos 5, Helena de Souza Pereira 1, Selma Ribeiro de Paiva 2, Izabel Christina Nunes de Palmer Paixão 1
The worldwide distribution of herpes simplex virus type 1 (HSV-1) allied to the emergence of resistant strains makes necessary and urgent the search and development of new substances capable of preventing and treating HSV-1 infections. Studies demonstrate synergy between genital herpes and human immunodeficiency virus type 1 (HIV-1), which represents a major concern for global public health.
The objective of this study was to evaluate the activity of crude extracts and isolated substances from in the replication of the HSV-1 virus and HIV-1-RT activity.
This study evaluated the activity of extracts and isolated compounds from Planch. & Triana against HSV-1 using Vero cells in culture and against HIV-1 using a recombinant reverse transcriptase enzyme (HIV -1 RT). The percentage of inhibition against HSV-1 was determined from viral lysis plaque reduction assay, and the anti-HIV-1-RT test was performed by a fluorimetric assay. It was also evaluated the cytotoxic activity of the samples using MTT [3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide].
The crude extracts showed high percentage of inhibition against HSV-1, reaching 81.4 to 100.0% inhibition in non-cytotoxic concentration (50 µg/mL). The isolated compounds, lanosterol and clusianone, demonstrated 100% inhibition in non-cytotoxic concentration (50 µg/mL). We also examined the effects of the extracts and isolates on the activity of the HIV-1-RT. Among the crude extracts, only the methanolic extract of leaves and methanolic extract of stems showed inhibitory activity against HIV-1-RT. Regarding the isolated compounds, lanosterol showed a moderate activity.
Our data demonstrate that extracts and isolates compounds Planch. & Triana have promising antiviral activity inhibiting HSV-1 replication and HIV-1 by inhibiting the anti-RT activity.
A distribuição mundial do vírus herpes simplex tipo 1 (HSV-1) aliada ao surgimento de cepas resistentes torna necessária e urgente a busca e o desenvolvimento de novas substâncias capazes de prevenir e tratar infecções HSV-1. Estudos demonstram sinergia entre herpes genital e vírus da imunodeficiência humana tipo 1 (HIV-1), o que representa uma grande preocupação para a saúde pública global.
O objetivo deste estudo foi avaliar a atividade de extratos brutos e substâncias isoladas de na replicação do vírus HSV-1 e na atividade anti HIV-1-RT.
Este estudo avaliou a atividade de extratos e substâncias isoladas de contra o HSV-1 utilizando células Vero em cultura e contra o HIV-1 utilizando a enzima transcriptase reversa recombinante (HIV-1 RT). A porcentagem de inibição contra o HSV-1 foi determinada a partir do ensaio de redução de placas de lise viral, e o ensaio anti-HIV-1 RT foi realizado por um ensaio fluorimétrico. Também foi avaliada a atividade citotóxica das amostras utilizando MTT [brometo de 3- (4,5-dimetiltiazol-2-il) -2,5-difeniltetrazólio].
Os extratos demonstraram elevada percentagem de inibição contra o HSV-1, atingindo 81,4 a 100,0% de inibição em concentração não citotóxica (50 µg/mL). Os compostos isolados, lanosterol e clusianona, demonstraram 100% de inibição em concentração não citotóxica (50 µg/mL). Examinamos também os efeitos dos extratos e isolados sobre a atividade anti-HIV-1 RT. Entre os extratos brutos, apenas o extrato metanólico das folhas e caules apresentaram atividade anti-HIV-1 RT. Em relação aos compostos isolados, lanosterol mostrou uma atividade moderada.
Nossos dados demonstram que os extratos e compostos isolados de possuem atividade antiviral promissora inibindo a replicação do HSV-1 e HIV-1 através da inibição da atividade anti-RT.
Herpes simplex virus 1 (HSV-1) and herpes simplex virus 2 (HSV-2), two serious human pathogens, are members of the
HSV-1 is commonly associated with orofacial infections and encephalitis. The public health impact of orolabial herpes caused by HSV-2 is probably small, being this virus primarily responsible for genital infections; however, recent studies have shown that HSV-1 infections also account for a substantial proportion of genital herpes infections3.
Prevalence of HSV-1 infection is higher in most geographic areas worldwide and more prevalent than HSV-2 infection in non-high-risk populations. Exceptions are groups of immunocompromised patients, such as HIV-positive individuals. Most studies show that HSV-1 infection is acquired during childhood and adolescence, and HSV-1 prevalence increases consistently with age across the age spectrum or stabilizes after age 304.
Several clinical and epidemiological studies demonstrate synergy between genital herpes and human immunodeficiency virus type 1 (HIV-1). HIV-1 is the etiologic agent of acquired immunodeficiency syndrome (AIDS) and is still a major concern for global public health. HSV infections are regularly associated with transient depression of cell-mediated immunity, since there is a close relationship between viruses infections and cellular immunological competence of the host. Currently, there is no treatment capable of curing genital herpes and AIDS, and there is no effective vaccine for HSV and HIV-1 yet. Furthermore, only few antiviral drugs are able of shortening the disease and prevent breakouts. These antiviral drugs decrease the rate of virus replication, giving more opportunity for the immune system interference5.
Although antiviral drugs such as acyclovir, famciclovir and valacyclovir show to be efficient and safe, the emergency of resistant HSV strains has been documented, and an aggravating situation is the fact that HSV is usually resistant to the three of them simultaneously, which decreases treatment options. In fact, the only tools to reduce morbidity and mortality associated with AIDS and its complications are still the prevention and the use of antiretroviral drugs. The antiretroviral drugs act by interacting with major viral proteins of the replication cycle of the virus. The resistance to antiretroviral drugs is largely unavoidable due to the error-prone nature of HIV reverse transcriptase (RT) and its lack of a proofreading function6.
The need for search and development of new substances capable of preventing and treating infections with HSV-1, HSV-2 and HIV-1 makes natural products interesting targets for assays involving evaluation of antiviral activity.
Among the botanical families, Clusiaceae was chosen because of its great representativeness in Brazil and the description of the use of its species in folk medicine. It comprises 14 botanical genera and is chemically characterized mainly by the presence of xanthones, polyisoprenylated benzophenones, flavonoids and terpenes7,8,9,10,11.
The objective of this study was to evaluate the activity of crude extracts and isolated substances from
Leaves, stems and flowers from a male individual and fruits from a female individual of
Leaves, fruits and stems of
Clusianone (
Lanosterol (C30H50O) characterization is made by 1H-NMR (400MHz, CDCl3) and 13C-NMR (100 MHz, CDCl3). 1H-NMR (400MHz, CDCl3): δH: 0.76 (s, 3H, 18-Me), 0.81 (s, 3H, 29-Me), 0.88 (s, 3H, 30-Me), 0.86 (d, 3H, 21-Me), 0.96 (s, 3H, 19-Me), 1.01 (s, 3H, 28-Me), 1.13 (m, 1H, 5-H), 1.31 (m, 1H, 20-H), 1.52 (m, 1H, 17-H), 1.61 (s, 3H , 27-Me), 1.69 (s, 3H, 26-Me), 3.25 (dd, J = 4.4, 11.6 Hz, 1H, 3-H), 5.10 (s, 1H, 24-H); 13C-NMR (CDCl3): δC: 15.7 (C-18), 15.8 (C-29), 17.9 (C-27), 19.1 (C-6), 19.2 (C-21), 20.4 (C-19), 21.7 (C-11), 24.7 (C-30), 25.0 (C-23), 25.9 (C-26), 27.9 (C-7), 28.2 (C-2), 28.3 (C-28), 28.4 (C-16), 30.0 (C-15), 31.1 (C-12), 35.5 (C-20), 35.6 (C-22), 36.1 (C-1), 37.5 (C-10), 39.2 (C-4), 44.3 (C-13), 49.9 (C-14), 50.3 (C-5), 51.2 (C-17), 79.2 (C-3), 125.4 (C-24), 131.1 (C-25), 133.8 (C-9), 134.3 (C-8).
Vero cells were cultured in Dulbecco's modified Eagle's medium (GIBCO) supplemented with 5% fetal bovine serum (FBS; HyClone, Logan, Utah), 100 U/mL penicillin, 100 µg/mL streptomycin, and amphotericin B (25 mg/mL; Cultilab, São Paulo, Brazil), at 37 ºC in a humidified 5% CO2 atmosphere. Herpes simplex virus type 1 (HSV-1, strain KOS) obtained from Departamento de Virologia Universidade Federal de Santa Catarina, Brazil, was routinely grown. Vero cells and virus stock cultures were prepared from supernatants of infected cells and stored at -80 ºC until use.
Monolayer of Vero cells in 96-multiwell plates were treated with 25, 50, 100 and 200 µg/mL of the plant extracts, and 50, 250, 500 and 1000 µM of the pure compounds, for 72 h/37 °C. After that, 1 mg/mL solution of 3-(4-5 dimethylthiazol-2yl)-2-5- diphenyl tetrazolium bromide (MTT; Sigma) was added (50 µL/well) to evaluate cell viability according to procedures described elsewhere15. The 50% cytotoxic concentration (CC50) was calculated by linear regression analysis of the dose-response curves.
The antiviral effect was evaluated by plaque reduction assay6. Substances and extracts at 50 µg/mL were added 1 h after addition of viral dilution and left for 20 h. After 20 h, cells were lysed, and the title of supernatant virus was determined by adding different dilutions on plate to verify the viral plaque reduction. The result was obtained by counting PFU, comparing cells treated with the substances and cells of viral control16,17.
An EnzChek RT Assay Kit (Molecular Probes) was used for detecting the RT activity. The mixture of 350 base-poly (A) ribonucleotide template and oligo d(T)16 primer was incubated at room temperature for 1 h. Then, the mixture was added into the tube containing polymerizing buffer (63 mM Tris-HCl, pH 8.1, 8 mM MgCl2, 132 mM NaCl, and 13 mM DTT). The reaction was started by adding the purified enzyme (1 µg/mL) into reaction mixture. The samples were incubated at 37 °C for 30 minutes and stopped by adding 200 mM EDTA. Then, the polymerizing activity was measured using a fluorometric assay by adding PicoGreen in TE buffer (10 mM Tris-HCl, pH 7.5, 1 mM EDTA) to the EDTA-terminated reaction mixture and incubated for 10 minutes on ice and in the dark. The background fluorescence was normalized by subtracting a control reaction value, and the fluorescence intensity was measured in microplate reader Thermomax (Molecular Devices) by using excitation and emission at 502 and 523 nm, respectively.
Results of anti-HIV-1 RT activity were expressed as means ± SD of three determinations. The IC50 values were calculated using the Microsoft Excel program. Results were considered significant if the p < 0.05.
A portion (1.0956 g) of the crude hexanic extract from flowers of
The crude extracts showed high percentage of inhibition against the HSV-1 virus, reaching 81.4 to 100.0% inhibition in non-cytotoxic concentration (50 µg/mL) (
aDetermined at 50 µM; ND: not determined.
aDetermined at 50 µM.
The anti-HIV-1 activities of extracts and isolated products from
Previous studies showed that the hexanic extracts of leaves and stems of
The hexanic extract of the flowers of
Clusianone is the major component of the flowers of
In the study conducted with clusianone isolated from the fruits of
The acetonic extracts of fruits and stems are expected to be composed by substances with medium to high polarity, such as benzophenones, while the methanolic extracts of leaves, fruits and stems are expected to have a high content of substances with higher polarity, such as flavonoids and flavonoids glucosydes. Silva and Paiva26 determined the flavonoid content (as flavones and flavonols) of these extracts, together with their antioxidant activity. The extracts evaluated showed a relative high percentage of these substances, which may also be responsible for their antiviral activities27,28.
The results corroborate that plant extracts are a valuable source of substances with antiviral activities. This study showed that
. Universidade Federal Fluminense, Instituto de Biologia. Outeiro de São João Batista, s/n - Campus do Valonguinho, Centro. Niterói (RJ), Brazil. CEP: 24210-130. Tel: +55 (21) 2629-2375, +55 (21) 2629-2376, +55 (21) 99973-7508. Fax: +55 (21) 2629-2375. E-mail: izabeluff@gmail.com
Received: 21/10/2015
Accepted: 20/12/2015